key: cord-0761247-eszhtrze
authors: Olmos, Carla Vallejos; Trahan, Sylvain; Rochon, Antoine; Ducharme, Anique
title: Severe myocarditis after SARS-CoV-2 vaccination in a 49-year-old woman
date: 2022-04-25
journal: CMAJ
DOI: 10.1503/cmaj.211687
sha: 49cf5c62fe6b8460ec080834076900282fda7063
doc_id: 761247
cord_uid: eszhtrze

Although myocarditis typically occurs within a week after mRNA-COVID-19 vaccination, delayed localized skin hypersensitivity reactions have been described a median of 7 days after vaccination. Few histopathological reports of patients with myocarditis after mRNA-SARS-CoV-2 vaccination have been published. In mild cases, nonspecific changes without infiltrates suggestive of active inflammation have been found at endomyocardial biopsy, raising the possibility of a sampling error owing to patchy infiltration. Here, Olmos et al examine the case of a 49-year-old woman with severe myocarditis after SARS-CoV-2 vaccination.

• We present a case of severe myocarditis in a middle-aged woman that required extracorporeal membrane oxygenation support and that appeared to respond to steroid treatment.

• Despite the possibility of this severe adverse reaction, the benefits of vaccination against SARS-CoV-2 far outweigh the risks. Note: ALT = alanine aminotransferase, AST = aspartate aminotransferase, hs-CRP = high-sensitivity C-reactive protein, hs-cTNT = high-sensitivity cardiac troponin T, LVEF = left ventricular ejection fraction, NA = not applicable, NT-proBNP = N-terminal pro brain natriuretic peptide.

was 100/60 mm Hg, her oxygen saturation was 95% on room air and her respiratory rate was 28 breaths/min. We heard a third heart sound but no murmur. Jugular venous pressure was elevated and urine output was reduced (10 mL/h). A repeat echocardiogram showed severe biventricular dysfunction, markedly increased cardiac wall thickness (suggestive of edema) and a small pericardial effusion (Appendix 1, Video 1, available at www.cmaj.ca/lookup/doi/10.1503/cmaj.211687/tab-related-content). Despite escalation of inotropic support, the patient's clinical condition worsened, with arrhythmic instability and recurrent ventricular fibrillation cardiac arrest. We intubated her and administered intravenous methylprednisolone (1000 mg/d for 3 d) for possible giant cell or autoimmune myocarditis, given her fulminant course. We started peripheral venoarterial extracorporeal membrane oxygenation (VA-ECMO) about 48 hours after initial presentation. We performed a right ventricle endomyocardial biopsy under ECMO support, which showed cardiomyocyte damage with moderate inflammatory infiltrates composed of small lymphocytes, macrophages and eosinophils, consistent with a diagnosis of eosinophil-rich lymphocytic myocarditis ( Figure 2 ). We did not observe any large areas of myocyte necrosis, granulomas or giant cells. The patient's hospital course was complicated by acute kidney injury requiring renal replacement therapy, and ventilatorassociated pneumonia. An enzyme-linked immunosorbent assay was positive for immunoglobulin (Ig) G antibodies against SARS-CoV-2 but negative for IgM, indicating previous vaccination and no acute infection. Several nasal PCR tests were negative for SARS-CoV-2. An autoimmune screening panel was negative. We stopped the ECMO on day 5; the patient's cardiac wall thickness had normalized and her LVEF improved to 40% (Appendix 2, Video 2, available at www.cmaj.ca/lookup/ doi/10.1503/cmaj.211687/tab-related-content). We successfully extubated her and tapered the corticosteroids. However, she developed a generalized multiform erythematous rash and high eosinophil count (5.68 [normal 0.02-0.50] × 10 9 /L). We restarted cortico steroids and the rash resolved within 24 hours.

We transferred the patient to a rehabilitation centre 35 days after her initial presentation. At transfer, she was taking oral prednisone (15 mg/d) and her eosinophil count had normalized.

Our patient presented with features typical of hypersensitivity myocarditis after receiving an mRNA vaccine as her second dose against SARS-CoV-2. 1 Unlike previous reports of myocarditis, mostly among young men, 2 our patient was a middle-aged woman who had received a mixed vaccine regimen and developed cardiogenic shock requiring ECMO support.

Although myocarditis typically occurs within a week after mRNA-COVID-19 vaccination, 3-10 delayed localized skin hypersensitivity reactions have been described a median of 7 days after vaccination. Few histopathological reports of patients with myocarditis after mRNA-SARS-CoV-2 vaccination have been published. In mild cases, nonspecific changes without infiltrates suggestive of active inflammation have been found at endomyocardial biopsy, raising the possibility of a sampling error owing to patchy infiltration. 3, 9 In 2 patients with cardiogenic shock, histopathology showed multifocal cardiomyocyte damage, with mixed infiltration of macrophages, T cells, eosinophils and B cells, suggesting an antibody-mediated mechanism. 11 Like our patient, and in contrast to milder cases, these patients were middle-aged (a 45-year-old woman and a 42-year-old man), developed symptoms later (10 d after her first dose and 14 d after his second dose, respectively) and received only mRNA vaccines. One patient recovered completely after 2 weeks of inotropic support and treatment with corticosteroids, but the other died within 3 days of clinical presentation. 11 Given the temporal relation between our patient's symptoms and the administration of the SARS-CoV-2 vaccine, and the pathology findings, it is probable that her condition was etio logically related to the vaccine. 12 Her score on the Naranjo Adverse Drug Reaction Probability Scale was 7 (https://www.evidencio.com/ models/show/661; Appendix 3, available at www.cmaj.ca/lookup/ doi/10.1503/cmaj.211687/tab-related-content), suggesting a probable adverse drug reaction (score 5-8).

The patient's endomyocardial biopsy findings were consistent with a diagnosis of hypersensitivity myocarditis, despite little necrosis, as may have been expected in such a fulminant presentation. Potential explanations for the lack of necrosis include the short time between cardiogenic shock and biopsy (< 12 h), such that myocardial necrosis had not yet occurred; sampling error, as patchy myocardial damage was seen on the cardiac magnetic resonance imaging that was performed later; or, less likely, extremely rapid response to high-dose corticosteroid treatment. 13 Hypersensitivity myocarditis with a fulminant course may be a rapidly fatal manifestation of drug rash with eosinophilia and systemic symptoms (DRESS) syndrome, which can occur after any drug administration, including vaccines. 13 Peripheral eosinophilia and cutaneous rash at presentation are typical, but cardiac involvement is uncommon; when it occurs, myocyte necrosis and eosinophilic infiltrates are found on endomyocardial biopsy, and treatment requires aggressive immunosuppression. 13 Although our patient did not initially exhibit all features typical of DRESS (Box 1), the temporal association between her symptom onset, mRNA SARS-CoV-2 vaccination and eosinophil-rich lymphocytic myocarditis suggests an autoreactive T-cell mechanism against the myocardium, perhaps by increased expression of cardiac autoantibodies specific to human leukocyte antigen after immunization in genetically predisposed patients. 13 Although the role of corticosteroid treatment in acute myocarditis is controversial, it might be considered in patients with a fulminant presentation or when autoimmune myocarditis is suspected. 13 Corticosteroids seemed beneficial in our patient, as well as for another patient in a recent report; 11 a prolonged taper of corticosteroids may be considered in some cases.

Previous reports did not describe their patients' detailed vaccination regimen, but most cases occurred a few days after a second dose of an mRNA vaccine against SARS-CoV-2. Whether the use of an adenovirus-based vaccine for the patient's first dose, followed by a second dose using an mRNA vaccine, played a role in our patient's fulminant presentation by triggering a stronger immunologic response is unknown, but warrants surveillance as many countries have adopted such a regi men, including the United Kingdom and United States (for the Johnson & Johnson adenoviral vaccine). Observational data suggest that this regimen provides a good safety profile, with a more robust humoural and cellular immunity than the homologous mRNA vaccine schedule, 15 but also a higher rate of common adverse effects, possibly by a synergistic mechanism. Finally, it is possible that our patient had a systemic overreaction, resulting from the interplay between activation of proinflammatory cascades and immunological pathways (type IV hypersensitivity reaction) induced by the heterologous vaccination treatment and genetic predisposition. 16 A fulminant presentation of myocarditis after SARS-CoV-2 vaccination is very rare and the remarkable efficacy of vaccines at preventing severe COVID-19 means that their benefits clearly outweigh their risks.

Myocarditis and pericarditis after mRNA COVID-19 vaccination

Surveillance of myocarditis (inflammation of the heart muscle) cases between

Myocarditis following immunization with mRNA COVID-19 vaccines in members of the US military

Myocarditis and pericarditis after vaccination for COVID-19

Myocarditis occurring after immunization with mRNA-based COVID-19 vaccines

Myocarditis following COVID-19 mRNA vaccination

Myocarditis after BNT162b2 and mRNA-1273 vaccination

Temporal relation between second dose BNT162b2 mRNA COVID-19 vaccine and cardiac involvement in a patient with previous SARS-COV-2 infection

Myocarditis temporally associated with COVID-19 vaccination

In-depth evaluation of a case of presumed myocarditis after the second dose of COVID-19 mRNA vaccine

Myocarditis after COVID-19 mRNA vaccination

Myocarditis and pericarditis after COVID-19 mRNA vaccination: practical considerations for care providers

Fulminant myocarditis: a comprehensive review from etiology to treatments and outcomes

Drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms (DRESS): an update in 2019

A 'mix and match' approach to SARS-CoV-2 vaccination

Could Sars-coronavirus-2 trigger autoimmune and/or autoinflammatory mechanisms in genetically predisposed subjects?

Visual elements (e.g., tables of the differential diagnosis, clinical features or diagnostic approach) are encouraged. Consent from patients for publication of their story is a necessity. See information for authors at www.cmaj.ca. Videos of perioperative transesophageal echography of a 49-year-old woman with myocarditis are available in Appendix 1 and Appendix 2, available at www

This article has been peer reviewed.The authors have obtained patient consent. Contributors: All of the authors contributed to the conception and design of the work, drafted the manuscript, revised it critically for important intellectual content, gave final approval of the version to be published and agreed to be accountable for all aspects of the work.

This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY-NC-ND 4.0) licence, which permits use, distribution and reproduction in any medium, provided that the original publication is properly cited, the use is noncommercial (i.e., research or educational use), and no modifications or adaptations are made. See: https://creativecommons.org/licenses/by-nc-nd/4.0/ Correspondence to: Anique Ducharme, anique.ducharme@umontreal.ca